OncoSec Medical To Present at Three Events in November
November 03 2014 - 6:02AM
Business Wire
OncoSec Medical Inc. (OTCQB: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, will present at
three events in November. The Company’s agenda is as follows:
BIO-Europe International Partnering Conference
Dr. Robert H. Pierce, Chief Scientific Officer, will present a
corporate overview of the Company at the 20th Annual BIO Europe
International Partnering Conference, taking place November 3-5,
2014 in Frankfurt, Germany. The presentation is part of the
Immunotherapy track and is scheduled to begin at 11:30 AM CET on
Tuesday, November 4th.
BIO-Europe® is Europe's largest partnering conference serving
the global biotechnology industry. The conference annually attracts
leading dealmakers from biotech, pharma and finance along with the
most exciting emerging companies. Produced with the support of BIO,
it is regarded as a “must attend” event for the biotech industry.
For more information, please visit
http://www.ebdgroup.com/bioeurope/index.php
Drexel Hamilton Micro-Cap Investor Forum
Jordyn Kopin, Associate Director of Corporate Communications,
will present a corporate overview of the Company at the Drexel
Hamilton Micro-Cap Investor Forum, taking place November 13th, 2014
in New York City, New York. The presentation is scheduled to begin
at 10 AM EST.
The Drexel Hamilton Micro-Cap Investor Forum is an interactive
industry conference for institutional investors. The conference
will feature one-on-one meeting opportunities with presenting
companies and provide an interactive environment meant to
facilitate networking and discussion. For more information, please
visit http://drexelhamilton.com/research/conferences/
Brean Capital Life Sciences Summit Conference
Punit Dhillon, President and CEO, will present a corporate
overview of the company at the Brean Capital Life Sciences Summit.
The event will take place November 24th, 2014 in New York City, New
York.
The Brean Capital Life Sciences Summit is an industry-specific
investment conference designed to facilitate the interaction of
company management and institutional investors. The goal of each
Brean Capital conference is to provide institutional investors with
high-level access to senior management and industry experts and
designed to connect the dots and provide original outlook and
depth. For more information please visit:
http://www.breancapital.com/profile/conferences/
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse intratumoral cancer immunotherapy. OncoSec
Medical's core technology is designed to
enhance the local delivery and uptake of DNA IL-12 and
other DNA-based immune-targeting agents. Clinical studies of
ImmunoPulse have demonstrated an acceptable safety profile and
preliminary evidence of anti-tumor activity in the treatment of
various skin cancers, as well as the potential to initiate a
systemic immune response without the systemic toxicities associated
with other treatments. OncoSec's lead program evaluating
ImmunoPulse for the treatment of metastatic melanoma is currently
in Phase 2 development, and is being conducted in collaboration
with several prominent academic medical centers. As the company
continues to evaluate ImmunoPulse in its current indications, it is
also focused on identifying and developing new immune-targeting
agents, investigating additional tumor indications, and evaluating
combination-based immunotherapy approaches. For more information,
please visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
OncoSec Medical Inc.Investor Relations:Jordyn Kopin,
855-662-6732investors@oncosec.comorDian Griesel, Int’l.Public
Relations:Laura Radocaj, 212-825-3210lradocaj@dgicomm.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024